Sorensen to head Siemens Healthcare in U.S., Canada

Justine Varieur Cadet | | Health Imaging | Oncology Imaging
Source: Siemens Healthcare
Siemens Healthcare has appointed neurologist Gregory Sorensen, MD, as CEO of Siemens Healthcare in the U.S., effective June 1. Sorensen succeeds Randy Hill, who has served as interim CEO. Sorensen also will oversee the Canadian activities of Siemens Healthcare.

Sorensen will be responsible for leading the marketing, sales, service and support functions for Siemens Healthcare in the U.S. and Canada, across the entire healthcare portfolio including medical imaging, therapy, health IT and laboratory diagnostics. He will be based at Siemens Healthcare's U.S. headquarters in Malvern, Pa.

Sorensen is currently serving as professor of radiology and health sciences & technology at Harvard Medical School; is a faculty member of the Harvard-Massachusetts Institute of Technology division of health sciences and technology; and co-director of the A.A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital in Boston.

He is a practicing neuroradiologist whose research has focused on novel oncology agents, such as gene therapy.

Justine Varieur Cadet

Related Content

High-intensity focused ultrasound could allow prostate cancer patients to avoid surgery
MRI-first approach could allow many to safely forego prostate biopsy
MRI guidance significantly reduces radiotherapy side effects compared to CT
Interventional procedure often as effective as surgery for difficult-to-treat liver cancer
AI tumor volume estimations could improve prostate cancer treatment strategies
MRI could be 'powerful tool' for guiding surgery decisions in patients with rectal cancer

Around the web

Radiology Business
AI can help radiology standardize image exam data labeling

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.